Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were obese and suffered from type 2 diabetes, took orforglipron for nine months as part of a trial, losing an average of 7.2kg (16 pounds).

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were the same as those with the injectable obesity drugs.